Caszyme | BiotechTV

top of page

BIO-Europe: Spain's Integra Therapeutics announced today that it has licensed novel Cas12l nucleases from Lithuania-based Caszyme as it continues to develop its gene writing platform

Integra CEO Avencia Sánchez-Mejías and Caszyme CEO Monika Paulė discuss the deal and explain why Cas12l's small size gives it...

Company News

Nov 4, 2024

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

Learn more about Allucent

bottom of page

BIO-Europe: Spain's Integra Therapeutics announced today that it has licensed novel Cas12l nucleases from Lithuania-based Caszyme as it continues to develop its gene writing platform

Follow BiotechTV

Sponsors

Sponsor Spotlight